Cellectis SA share price logo

Cellectis SA

NASDAQ: CLLS

Small Cap

$3.94

+0.18

(+4.79%)

as on

Cellectis SA Stock Performance

as on May 7, 2026 at 6:58 am IST

  • Day's Low

    Day's High

    $3.81
    $3.99
    downward going graph

    3.30%

    Downside

    1.27%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.33
    $5.48
    downward going graph

    66.32%

    Downside

    39.08%

    Upside

    downward going graph

Cellectis SA share price movements today

Previous Close
$3.76
Open
$3.90
Volume
133.9K
Day's Low - High
$3.81 - $3.99
52 Week Low - High
$1.33 - $5.48

Cellectis SA Historical Returns

1 Month Return
+ 9.3 %
3 Month Return
+ 5.32 %
1 Year Return
+ 137.97 %
3 Year Return
+ 97.89 %
5 Year Return
-75.79 %

Cellectis SA Stock Fundamentals & Key Indicators

Check Cellectis SA market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$372.2M

EPS (TTM)

-0.982

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-21.8M

Revenue (TTM)

79.6M

Profit Margin

-84.92%

Return On Equity TTM

-65.33%

Cellectis SA vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cellectis SA with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Cellectis SA image
Cellectis SA
BUY$372.2M-75.79%NA-84.92%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$40.2B127.94%75.8512.55%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$107.9B99.08%25.1832.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$33.1BNA120.445.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$73.6B40.83%17.1329.65%

Stock Returns calculator for Cellectis SA Stock including INR - Dollar returns

The Cellectis SA stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cellectis SA investment value today

Current value as on today

₹2,79,848

Returns

₹1,79,848

(+179.85%)

Returns from Cellectis SA Stock

₹1,49,367 (+149.37%)

Dollar Impact

₹30,481 (+30.48%)

Analyst Recommendation on Cellectis SA Stock

Based on 14 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 14 analysts, 85.71% of analysts recommend a 'BUY' rating for Cellectis SA. Average target price of $7.25

Cellectis SA Share Price Target

Get share price movements and forecasts by analysts on Cellectis SA.

What analysts predicted

45.66%UPSIDE

Target Price

$7.25

Current Price

$3.94

Analyzed by

14 Analysts

Target

$7.25

Cellectis SA target price $7.25, a slight upside of 45.66% compared to current price of $3.94. According to 14 analysts rating.

Indian Investors' Interest in Cellectis SA Stock

Search interest for Cellectis SA Stock has increased by 70% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:70% versus previous 30 day period

Cellectis SA Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
0
0
4
8
16
12
10
16
35
10
Gross Profit
0
0
2
6
13
10
8
14
32
-2
Operating Income
-20
-29
-20
-17
-10
-10
-14
-9
8
-24
EBITDA
-11
-56
11
-18
-16
14
-11
-16
7
-19
Interest Expense
1
17
1
1
2
1
1
2
2
2
Depreciation
4
5
4
4
4
5
4
5
5
5
Income Before Tax
-17
-63
5
-25
-23
6
-18
-23
0
-33
Income Tax Expense
0
0
0
0
0
0
0
0
-
-2
Net Income
-17
-42
5
-25
-23
5
-18
-23
0
-26
Net Profit Margin
-11278.71%
-15145.58%
124.62%
-313.48%
-142.32%
46.57%
-170.14%
-141.91%
1.67%
-252.97%

Cellectis SA Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
42
25
12
15
73
73
19
0
41
73
Gross Profit
40
22
9
3
37
37
17
-6
32
53
Operating Income
-63
-92
-105
-123
-85
-85
-89
-97
-59
-40
EBITDA
-65
-108
-102
-116
-75
-68
-71
-92
-9
-20
Interest Expense
0
0
0
2
12
5
3
5
7
8
Depreciation
-
3
2
6
9
16
18
18
19
20
Income Before Tax
-63
-103
-88
-115
-97
-97
-98
-116
-36
-74
Income Tax Expense
-1
-13
16
-24
-24
-11
0
0
-6
-7
Net Income
-63
-99
-78
-90
-72
-86
-98
-101
-36
-67
Net Profit Margin
-150.10%
-394.51%
-618.12%
-597.01%
-98.14%
-116.68%
-514.78%
-13385.30%
-88.57%
-92.66%

Cellectis SA Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-63
5
-25
-23
5
-18
-23
0
-26
Operating Cash Flow
39
-23
52
-5
0
-17
-10
-1
-10
Investing Cash Flow
-13
-2
-106
22
-16
4
-52
-3
22
Financing Cash Flow
41
11
78
-4
2
-4
-4
-4
-4
Change in Cash
69
-13
26
10
-15
-15
-67
-7
9

Cellectis SA Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-103
-88
-115
-53
-96
-98
-116
-36
-67
Operating Cash Flow
-52
-68
-69
-80
-104
-87
-24
22
-40
Investing Cash Flow
1
35
-35
-54
7
-2
-15
-102
-29
Financing Cash Flow
41
236
-3
27
47
1
82
89
-16
Change in Cash
1
195
-110
-99
-55
-92
43
6
-79

Global Institutional Holdings in Cellectis SA

Funds
Holdings
Citigroup Inc
0%
Citadel Advisors Llc
0.22%
Virtu Financial LLC
0.03%
B Group, Inc
3.26%
First Affirmative Financial Network
0.01%
See all

Cellectis SA News & Key Events

    Insights on Cellectis SA

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 1 year, CLLS stock has moved up by 138.0%

    • imgPOSITIVE IMPACT

      Best in 3 Years

      img

      In the last 3 years, CLLS has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Best in 1 Year

      img

      In the last 1 year, CLLS has outperformed top 5 stocks with highest market-cap in its industry

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, 589.0K → -26.29M (in $), with an average decrease of 4564.9% per quarter

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 35.17M → 10.39M (in $), with an average decrease of 70.4% per quarter

    About Cellectis SA

    Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
    OrganisationCellectis SA
    Headquarters8, rue de la Croix Jarry, Paris, France, 75013
    IndustryBiotechnology
    CEODr. Andre Choulika Ph.D.
    E-voting on sharesClick here to vote

    Key Management of Cellectis SA

    Name

    Title

    Dr. Philippe Duchateau Ph.D.

    Chief Scientific Officer

    Pascalyne Wilson

    Director of Communications

    Ms. Kyung Nam-Wortman

    Executive VP & Chief Human Resources Officer

    Dr. Andre Choulika Ph.D.

    Co-Founder, CEO & Director

    Mr. Jean Charles Epinat Ph.D.

    Chief Technological Officer

    Valerie Cros

    Principal Financial Officer & Principal Accounting Officer

    Ms. Marie-Bleuenn Terrier

    General Counsel & Secretary of the Board of Directors

    Mr. Stephan Reynier M.Sc.

    Chief Regulatory & Pharmaceutical Compliance Officer

    Dr. David J. Sourdive Ph.D.

    Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director

    Mr. Arthur Stril

    CFO & Chief Business Officer

    FAQs

    What is Cellectis SA share price today?

    Cellectis SA share price today is $3.94 as on at the close of the market. Cellectis SA share today touched a day high of $3.99 and a low of $3.81.

    What is the 52 week high and 52 week low for Cellectis SA share?

    Cellectis SA share touched a 52 week high of $5.48 on and a 52 week low of $1.33 on . Cellectis SA stock price today i.e. is closed at $3.94,which is 28.10% down from its 52 week high and 196.89% up from its 52 week low.

    What is Cellectis SA's market capitalisation today?

    Cellectis SA market capitalisation is $0.00T as on .

    How to invest in Cellectis SA Stock (CLLS) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Cellectis SA on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cellectis SA Shares that will get you 0.3807 shares as per Cellectis SA share price of $3.94 per share as on May 7, 2026 at 1:28 am IST.

    What is the minimum amount required to buy Cellectis SA Stock (CLLS) from India?

    Indian investors can start investing in Cellectis SA (CLLS) shares with as little as ₹94.61 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹946.10 in Cellectis SA stock (as per the Rupee-Dollar exchange rate as on ). Based on Cellectis SA share’s latest price of $3.94 as on May 7, 2026 at 1:28 am IST, you will get 2.5381 shares of Cellectis SA. Learn more about fractional shares .

    What are the returns that Cellectis SA has given to Indian investors in the last 5 years?

    Cellectis SA stock has given -75.79% share price returns and 29.19% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?